However, He et al (37) reported that, for the second-line treatment of NSCLC with 30 mg/m2 LBP in combination with 75 mg/m2 TXT, an RR of 26.7% (4/15) and a DCR of 73.3% (11/15) were observed. This evidence concerns the gene LBP and non-small cell lung carcinoma.